http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
- 中文 을 입력하시려면 zhongwen을 입력하시고 space를누르시면됩니다.
- 北京 을 입력하시려면 beijing을 입력하시고 space를 누르시면 됩니다.
RISS 인기검색어
- 검색키워드
- 저자 : Dan Ning Sun (검색결과 3 건)
- 무료
- 기관 내 무료
- 유료
-
-
Ning Liu,WuHan Yu,Mengjiao Sun,Wenjing Zhang,Dan Zhou,Jing Sun,ManXia Wang 대한신경과학회 2023 Journal of Clinical Neurology Vol.19 No.4
Background and Purpose A systematic review and meta-analysis was performed of the outcome of Coronavirus disease 2019 (COVID-19) infection in patients with multiple sclerosis (MS) who received disease-modifying therapies (DMTs). Methods Relevant studies published before November 2022 in the PubMed, Cochrane Library, Chinese National Knowledge Infrastructure, and Web of Science databases were retrieved using the following search expression: (“multiple sclerosis” OR “MS”) AND (“DMT” OR “disease modifying therapies”) AND (“COVID-19”). Two authors independently screened the articles and extracted the data. Qualitative analyses and a meta-analysis constituted 22 of the 794 retrieved articles. Differences in the hospitalization and mortality rates were used as the main measures of efficacy, and the meta-analysis was performed using RevMan software. Results 22 clinical trials were selected. The hospitalization rate was lower in the 3,216 patients who received DMTs than in the 774 patients who did not receive any treatment, with a moderate effect size of 0.43 (p<0.00001). The mortality rate was also lower among patients with MS treated using DMTs than in controls (odds ratio [OR]=0.19, 95% confidence interval [CI]=0.13–0.27, p<0.00001). The hospitalization rates for COVID-19 infection in patients with MS treated with anti-CD20 therapy also increased markedly (OR=3.32, 95% CI=2.63–4.20, p<0.00001). However, there was no significant difference between patients with MS who did and did not receive DMTs. Conclusions In summary, the application of DMTs was found to be valuable for patients with MS infected with COVID-19. However, more clinical studies are needed to determine the use of anti-CD20 drugs in patients with MS during the COVID-19 pandemic.
-
Qian Sun,Chun Zeng,Meng-Meng Xing,Bo Chen,Dan Zhao,San-Guo Hong,Ning Zhang 성균관대학교(자연과학캠퍼스) 성균나노과학기술원 2019 NANO Vol.14 No.6
Deliberately engineering oxide composites on constructing and manipulating interactive structures particularly in surface layers was highly desirable for heterogeneous catalysis. Herein, upon the redox replacement reaction between Ce(IV) precursor (Ce(NO3)2- 6)and Cu2O nanosubstrate, an attempt to directly engineer the surface structure of Cu-based substrate was performed by the Ce(IV)–Cu2O etching-embedding process, then the obtained powders were thermo-treated to get a series of Ce–O–Cu catalysts with different Ce:Cu molar ratios for NH3 selective catalytic reduction (NH3-SCR) of NO. Characterized by ICP-OES, XRD, Raman, XPS, SEM, BET, H2-TPR, NO- and NH3-TPD measurements, it was demonstrated that the Cu–O–Ce catalysts were structured as CuO matrix with an interactive surface composed by co-present Cu(I)–Cu(II) and Ce(III)–Ce(IV) species, even the introduction of Ce was confined in a quite low loading range (0.83–2.3 wt.%); such a surface exhibited the distinct synergistic effect with positively manipulated physical-chemistry properties such as active site distributions, redox features and surface reactivity compared to pure CuO and traditional Cu–Ce composite catalyst, leading to attractive catalytic performance such as ≥ 90% NO conversion with ≥ 95% N2 selectivity and the two-fold TOF enhancement versus traditional catalysts, even SO2 was present in reactant mixture on well-manipulated catalyst (Ce loading at 1.6 wt.%) These results indicated that the etching-embedding strategy illuminated in this work could be referred as a feasible method to directly engineer and construct interactive oxide composite surface for advanced application as well as current efficient Ce–O–Cu catalytic interface for heterogeneous catalysis.
연관 검색어 추천
이 검색어로 많이 본 자료
활용도 높은 자료
